Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The Dementia Consortium supports collaborative target validation and drug discovery projects from academia and SMEs. We offer a unique collaborative model bringing together the charity and industry sectors to help accelerate development of therapies for novel dementia targets.
The Dementia Consortium provides drug discovery resources, project management, industry expertise and tools as well as full funding support for projects. We can support small molecule or antibody-based strategies and aim to generate tools to achieve preclinical target validation. Our ultimate goal is to progress successful projects from laboratories towards the clinic.
Característiques principals
Scope of projects:
  • Projects focused on novel molecular targets in any neurodegenerative disease (including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, Amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntingdon’s disease)
  • Evidence linking the target to human disease and confidence that target modulation would have a therapeutic effect
  • Collaborators with strong biology expertise and access to enabling assays, reagents and disease models

    The following projects are not in scope for funding:
  • Projects focused on well-studied targets and pathways for neurodegenerative diseases
  • In vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
  • Repurposing of existing drugs (although we will consider optimisation of tool / literature compounds to improve selectivity, potency, bioavailability, etc)
  • Non-pharmacological interventions (e.g. diet or exercise or other behavioural changes)

    Previous experience in drug discovery is not required, nor do you need to have any in-house capability for carrying out drug development. The Consortium, through MRC Technology, is able to provide all of the assay development, screening and medicinal chemistry resources required to develop novel compounds or antibodies against the target.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
    • Carol Barnwell, cbarnwell@imim.es. Ext.: 1670
    • Marta López, mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://www.dementiaconsortium.org/
    Impresos (URL)
    Please register your details to download the application form at:
    http://www.dementiaconsortium.org/for-researchers/#wpcf7-f94-p11-o1
    Requisits
  • Lead applicant should have contract which will cover their salary for at least the duration of the grant
  • Principal Investigators as co-applicants should have a tenured position
    • Dotació
    Typical costs £100-250k. Notional limit £500k, for exceptional cases
    Durada
    Typically up to 2 years.
    AVÍS IMPORTANT
    Open, ongoing application process. Expressions of interest are reviewed six times per year.
    For additional information on the application process, please see the Launch Event Slides.

    Arxius

    Arxiu
    Dementia-Consortium-Launch-Event-Final-ppt (2).pdf